Systematic review and meta-analysis of the effect of SGLT-2 inhibitors on microvascular outcomes in patients with type 2 diabetes: A review protocol

Edgar Gerardo Dorsey-Trevinõ, Belinda Maricela Contreras-Garza, José Gerardo González-González, Neri Álvarez-Villalobos, Alejandro Salcido-Montenegro, Alejandro Diáz González-Colmenero, Ann M. Farrell, Victoria González-Nava, Giselle Rodríguez-Tamez, Victor Manuel Montori, René Rodriguez-Gutierrez

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction Sodium glucose cotransporter 2 (SGLT-2) inhibitors are a relatively new drug-class of glucose-lowering medications. Several trials and systematic reviews have demonstrated their beneficial effect on some macrovascular outcomes. Their effect on microvascular outcomes has been reported as positive in several trials, however, their effect remains uncertain. Therefore, we report the protocol of a systematic review and meta-analysis aimed at determining the effect of SGLT-2 inhibitors regarding patient-important and surrogate microvascular outcomes in patients with type 2 diabetes. Methods and analysis A comprehensive search will be conducted to find eligible articles from each database's earliest inception to November 2017. These databases will include Ovid, MEDLINE, EMBASE, Web of Science, and Scopus. We will search for randomized controlled trials (RCTs) that compare any of the SGLT-2 inhibitors with any other active treatment or placebo assessing microvascular outcomes in either their primary or secondary outcomes. Reviewers working independently and in duplicate will review all abstracts, and full-text manuscripts for eligibility, and will systematically extract the data and will assess the risk of bias in the included studies. Random-effects models will also be used. Ethics and dissemination The results of the systematic review will be disseminated via publication in a peer-reviewed journal regardless of outcome and will be presented at relevant conferences. The data we will use do not include individual patient data, so ethical approval is not required PROSPERO registration number CRD42017076460.

Original languageEnglish (US)
Article numbere020692
JournalBMJ Open
Volume8
Issue number6
DOIs
StatePublished - Jun 1 2018

Fingerprint

Sodium-Glucose Transport Proteins
Type 2 Diabetes Mellitus
Meta-Analysis
Databases
Manuscripts
Ethics
MEDLINE
Publications
Randomized Controlled Trials
Placebos
Glucose
Pharmaceutical Preparations
Therapeutics

Keywords

  • diabetic neuropathy
  • diabetic retinopathy
  • peripheral vascularization
  • sglt-2

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Dorsey-Trevinõ, E. G., Contreras-Garza, B. M., González-González, J. G., Álvarez-Villalobos, N., Salcido-Montenegro, A., Diáz González-Colmenero, A., ... Rodriguez-Gutierrez, R. (2018). Systematic review and meta-analysis of the effect of SGLT-2 inhibitors on microvascular outcomes in patients with type 2 diabetes: A review protocol. BMJ Open, 8(6), [e020692]. https://doi.org/10.1136/bmjopen-2017-020692

Systematic review and meta-analysis of the effect of SGLT-2 inhibitors on microvascular outcomes in patients with type 2 diabetes : A review protocol. / Dorsey-Trevinõ, Edgar Gerardo; Contreras-Garza, Belinda Maricela; González-González, José Gerardo; Álvarez-Villalobos, Neri; Salcido-Montenegro, Alejandro; Diáz González-Colmenero, Alejandro; Farrell, Ann M.; González-Nava, Victoria; Rodríguez-Tamez, Giselle; Montori, Victor Manuel; Rodriguez-Gutierrez, René.

In: BMJ Open, Vol. 8, No. 6, e020692, 01.06.2018.

Research output: Contribution to journalArticle

Dorsey-Trevinõ, EG, Contreras-Garza, BM, González-González, JG, Álvarez-Villalobos, N, Salcido-Montenegro, A, Diáz González-Colmenero, A, Farrell, AM, González-Nava, V, Rodríguez-Tamez, G, Montori, VM & Rodriguez-Gutierrez, R 2018, 'Systematic review and meta-analysis of the effect of SGLT-2 inhibitors on microvascular outcomes in patients with type 2 diabetes: A review protocol', BMJ Open, vol. 8, no. 6, e020692. https://doi.org/10.1136/bmjopen-2017-020692
Dorsey-Trevinõ EG, Contreras-Garza BM, González-González JG, Álvarez-Villalobos N, Salcido-Montenegro A, Diáz González-Colmenero A et al. Systematic review and meta-analysis of the effect of SGLT-2 inhibitors on microvascular outcomes in patients with type 2 diabetes: A review protocol. BMJ Open. 2018 Jun 1;8(6). e020692. https://doi.org/10.1136/bmjopen-2017-020692
Dorsey-Trevinõ, Edgar Gerardo ; Contreras-Garza, Belinda Maricela ; González-González, José Gerardo ; Álvarez-Villalobos, Neri ; Salcido-Montenegro, Alejandro ; Diáz González-Colmenero, Alejandro ; Farrell, Ann M. ; González-Nava, Victoria ; Rodríguez-Tamez, Giselle ; Montori, Victor Manuel ; Rodriguez-Gutierrez, René. / Systematic review and meta-analysis of the effect of SGLT-2 inhibitors on microvascular outcomes in patients with type 2 diabetes : A review protocol. In: BMJ Open. 2018 ; Vol. 8, No. 6.
@article{5bca6e7879ac445eb52dd9f4b9bb0366,
title = "Systematic review and meta-analysis of the effect of SGLT-2 inhibitors on microvascular outcomes in patients with type 2 diabetes: A review protocol",
abstract = "Introduction Sodium glucose cotransporter 2 (SGLT-2) inhibitors are a relatively new drug-class of glucose-lowering medications. Several trials and systematic reviews have demonstrated their beneficial effect on some macrovascular outcomes. Their effect on microvascular outcomes has been reported as positive in several trials, however, their effect remains uncertain. Therefore, we report the protocol of a systematic review and meta-analysis aimed at determining the effect of SGLT-2 inhibitors regarding patient-important and surrogate microvascular outcomes in patients with type 2 diabetes. Methods and analysis A comprehensive search will be conducted to find eligible articles from each database's earliest inception to November 2017. These databases will include Ovid, MEDLINE, EMBASE, Web of Science, and Scopus. We will search for randomized controlled trials (RCTs) that compare any of the SGLT-2 inhibitors with any other active treatment or placebo assessing microvascular outcomes in either their primary or secondary outcomes. Reviewers working independently and in duplicate will review all abstracts, and full-text manuscripts for eligibility, and will systematically extract the data and will assess the risk of bias in the included studies. Random-effects models will also be used. Ethics and dissemination The results of the systematic review will be disseminated via publication in a peer-reviewed journal regardless of outcome and will be presented at relevant conferences. The data we will use do not include individual patient data, so ethical approval is not required PROSPERO registration number CRD42017076460.",
keywords = "diabetic neuropathy, diabetic retinopathy, peripheral vascularization, sglt-2",
author = "Dorsey-Trevin{\~o}, {Edgar Gerardo} and Contreras-Garza, {Belinda Maricela} and Gonz{\'a}lez-Gonz{\'a}lez, {Jos{\'e} Gerardo} and Neri {\'A}lvarez-Villalobos and Alejandro Salcido-Montenegro and {Di{\'a}z Gonz{\'a}lez-Colmenero}, Alejandro and Farrell, {Ann M.} and Victoria Gonz{\'a}lez-Nava and Giselle Rodr{\'i}guez-Tamez and Montori, {Victor Manuel} and Ren{\'e} Rodriguez-Gutierrez",
year = "2018",
month = "6",
day = "1",
doi = "10.1136/bmjopen-2017-020692",
language = "English (US)",
volume = "8",
journal = "BMJ Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "6",

}

TY - JOUR

T1 - Systematic review and meta-analysis of the effect of SGLT-2 inhibitors on microvascular outcomes in patients with type 2 diabetes

T2 - A review protocol

AU - Dorsey-Trevinõ, Edgar Gerardo

AU - Contreras-Garza, Belinda Maricela

AU - González-González, José Gerardo

AU - Álvarez-Villalobos, Neri

AU - Salcido-Montenegro, Alejandro

AU - Diáz González-Colmenero, Alejandro

AU - Farrell, Ann M.

AU - González-Nava, Victoria

AU - Rodríguez-Tamez, Giselle

AU - Montori, Victor Manuel

AU - Rodriguez-Gutierrez, René

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Introduction Sodium glucose cotransporter 2 (SGLT-2) inhibitors are a relatively new drug-class of glucose-lowering medications. Several trials and systematic reviews have demonstrated their beneficial effect on some macrovascular outcomes. Their effect on microvascular outcomes has been reported as positive in several trials, however, their effect remains uncertain. Therefore, we report the protocol of a systematic review and meta-analysis aimed at determining the effect of SGLT-2 inhibitors regarding patient-important and surrogate microvascular outcomes in patients with type 2 diabetes. Methods and analysis A comprehensive search will be conducted to find eligible articles from each database's earliest inception to November 2017. These databases will include Ovid, MEDLINE, EMBASE, Web of Science, and Scopus. We will search for randomized controlled trials (RCTs) that compare any of the SGLT-2 inhibitors with any other active treatment or placebo assessing microvascular outcomes in either their primary or secondary outcomes. Reviewers working independently and in duplicate will review all abstracts, and full-text manuscripts for eligibility, and will systematically extract the data and will assess the risk of bias in the included studies. Random-effects models will also be used. Ethics and dissemination The results of the systematic review will be disseminated via publication in a peer-reviewed journal regardless of outcome and will be presented at relevant conferences. The data we will use do not include individual patient data, so ethical approval is not required PROSPERO registration number CRD42017076460.

AB - Introduction Sodium glucose cotransporter 2 (SGLT-2) inhibitors are a relatively new drug-class of glucose-lowering medications. Several trials and systematic reviews have demonstrated their beneficial effect on some macrovascular outcomes. Their effect on microvascular outcomes has been reported as positive in several trials, however, their effect remains uncertain. Therefore, we report the protocol of a systematic review and meta-analysis aimed at determining the effect of SGLT-2 inhibitors regarding patient-important and surrogate microvascular outcomes in patients with type 2 diabetes. Methods and analysis A comprehensive search will be conducted to find eligible articles from each database's earliest inception to November 2017. These databases will include Ovid, MEDLINE, EMBASE, Web of Science, and Scopus. We will search for randomized controlled trials (RCTs) that compare any of the SGLT-2 inhibitors with any other active treatment or placebo assessing microvascular outcomes in either their primary or secondary outcomes. Reviewers working independently and in duplicate will review all abstracts, and full-text manuscripts for eligibility, and will systematically extract the data and will assess the risk of bias in the included studies. Random-effects models will also be used. Ethics and dissemination The results of the systematic review will be disseminated via publication in a peer-reviewed journal regardless of outcome and will be presented at relevant conferences. The data we will use do not include individual patient data, so ethical approval is not required PROSPERO registration number CRD42017076460.

KW - diabetic neuropathy

KW - diabetic retinopathy

KW - peripheral vascularization

KW - sglt-2

UR - http://www.scopus.com/inward/record.url?scp=85049747871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049747871&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2017-020692

DO - 10.1136/bmjopen-2017-020692

M3 - Article

C2 - 29961013

AN - SCOPUS:85049747871

VL - 8

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 6

M1 - e020692

ER -